Topical and Intralesional Immunotherapy for the Management of Basal Cell Carcinoma.

Publication date: Jun 04, 2024

Basal Cell Carcinoma (BCC) is the most common type of cancer among the white population. Individuals with fair skin have an average lifetime risk of around 30% for developing BCC, and there is a noticeable upward trend in its incidence rate. The principal treatment objectives for BCC involve achieving the total excision of the tumor while maximizing the preservation of function and cosmesis. Surgery is considered the treatment of choice for BCC for two main reasons: it allows for the highest cure rates and facilitates histological control of resection margins. However, in the subgroup of patients with low-risk recurrence or medical contraindications for surgery, new non-surgical treatment alternatives can provide an excellent oncological and cosmetic outcome. An evident and justified instance of these local therapies occurred during the COVID-19 pandemic, a period when surgical interventions carried out in hospital settings were not a viable option.

Open Access PDF

Concepts	Keywords
Cancers	basal cell carcinoma
Immunotherapy	BCC
Lifetime	BCC treatment
Principal	non-surgical treatment
White	skin cancer
	topical immunotherapy

Semantics

Type	Source	Name
disease	MESH	Basal Cell Carcinoma
pathway	KEGG	Basal cell carcinoma
disease	MESH	cancer
disease	VO	population
disease	MESH	medical contraindications
disease	MESH	COVID-19 pandemic
disease	VO	viable
disease	MESH	Carcinoma
drug	DRUGBANK	Coenzyme M
drug	DRUGBANK	Spinosad
disease	VO	effectiveness
disease	VO	effective
disease	MESH	skin cancer
drug	DRUGBANK	Methyprylon
disease	MESH	morbidity
disease	IDO	intervention
drug	DRUGBANK	Imiquimod
drug	DRUGBANK	Fluorouracil
pathway	REACTOME	Immune System
drug	DRUGBANK	Methyl aminolevulinate
disease	MESH	erythema
drug	DRUGBANK	Thymidine monophosphate
disease	MESH	death
disease	MESH	blister
disease	MESH	edema
disease	MESH	melanoma
pathway	KEGG	Melanoma
disease	VO	USA
drug	DRUGBANK	Aminolevulinic acid
drug	DRUGBANK	Alpha-Linolenic Acid
disease	VO	protocol
drug	DRUGBANK	Protoporphyrin
drug	DRUGBANK	Oxygen
disease	IDO	site
disease	MESH	hyperpigmentation
disease	MESH	scarring
disease	MESH	hidradenitis suppurativa
disease	MESH	acne
drug	DRUGBANK	Ingenol Mebutate
disease	MESH	actinic keratosis
disease	VO	dose
drug	DRUGBANK	Bleomycin
drug	DRUGBANK	Trestolone
disease	MESH	squamous carcinoma
disease	MESH	Hodgkin’s lymphoma
disease	MESH	vascular malformations
disease	MESH	keloid
disease	MESH	warts
disease	IDO	process
disease	MESH	infections
drug	DRUGBANK	Methotrexate
drug	DRUGBANK	Folic Acid
disease	IDO	production
disease	MESH	keratoacanthoma
drug	DRUGBANK	Diclofenac
drug	DRUGBANK	Calcitriol
drug	DRUGBANK	Sinecatechins
drug	DRUGBANK	Vitamin A
drug	DRUGBANK	Ascorbic acid
drug	DRUGBANK	Patidegib
drug	DRUGBANK	Calcipotriol
pathway	KEGG	Apoptosis
drug	DRUGBANK	Cholecalciferol
disease	MESH	paresthesias
drug	DRUGBANK	Solamargine
drug	DRUGBANK	Epigallocatechin
drug	DRUGBANK	Epigallocatechin gallate
drug	DRUGBANK	Green tea leaf
drug	DRUGBANK	Nonoxynol-9
drug	DRUGBANK	Alitretinoin
disease	MESH	Kaposi’s sarcoma
drug	DRUGBANK	Bexarotene
disease	MESH	lymphomas
drug	DRUGBANK	Tretinoin
drug	DRUGBANK	Adapalene
drug	DRUGBANK	Tazarotene
disease	VO	ineffective
drug	DRUGBANK	Etretinate
drug	DRUGBANK	Trifarotene
disease	IDO	history
disease	MESH	Gorlin syndrome
drug	DRUGBANK	Vismodegib
drug	DRUGBANK	Sonidegib
disease	VO	Viruses
disease	MESH	herpes simplex
disease	VO	macrophage
disease	IDO	colony
disease	IDO	cell
drug	DRUGBANK	Talimogene laherparepvec
drug	DRUGBANK	Nivolumab
drug	DRUGBANK	L-Asparagine
disease	IDO	replication
disease	VO	gene
disease	VO	lymphoma
disease	MESH	atopic dermatitis
disease	MESH	eczema
disease	VO	vaccine
disease	MESH	inflammation
drug	DRUGBANK	Cemiplimab
disease	MESH	Histocompatibility
drug	DRUGBANK	Natural alpha interferon
disease	IDO	immune response
drug	DRUGBANK	Bismuth subgallate
drug	DRUGBANK	Epinephrine
drug	DRUGBANK	Silver
drug	DRUGBANK	Tricyclazole
disease	MESH	metastases
disease	MESH	nevus
disease	MESH	syndrome
drug	DRUGBANK	Acitretin
drug	DRUGBANK	Dimethyl sulfoxide
disease	VO	report
drug	DRUGBANK	Sparfosic acid

Original Article

(Visited 2 times, 1 visits today)